Stepan's Self-Help Turnaround Is Working — Now It Has to Prove the Volume Is Structural

A doubled quarterly EPS, 7% organic volume in end markets growing 0-1%, and a quietly raised cost-out target — against a stock already up 30% in ninety days and still 50% below its 2021 peak.

SCL · Earnings Call · 2026-10-28

The quarter that looked like a different company

Stepan's third quarter was, on its face, the cleanest print in several years. Adjusted EBITDA of $66.3 million rose 18% year over year; adjusted diluted EPS of $0.94 nearly doubled from $0.48; reported net income of $17.8 million compared with $10.8 million. All three segments grew volume and earnings. Surfactants EBITDA jumped 27% to $48 million, Polymers added 4% to $23 million, and Specialty Products grew 5% to $11.7 million on 20% volume growth. Selling prices did a lot of the lifting in Polymers (+22%), which is really just the contractual pass-through of raw material inflation rather than pricing power — a nuance worth holding onto. What matters more is the shape of the recovery. The trailing year contains a quarter with a roughly $54 million operating loss (Project Catalyst restructuring charges), and the latest filed quarter shows the snap-back: operating income of $37 million, up 107% year over year. Gross margin of 14.6% is up 2.5 percentage points, though still far from the 21% of 2021. This is a business climbing out of a trough, not one compounding off a high.

The volume is the actual story

Strip out price and currency and what's left is the number management wants you to focus on: “Organic volume grew 7% with growth in all 3 segments” — Luis E. Rojo, President and CEO · 2026-10-28. Year to date that is roughly 4% organic volume growth — against end markets that CEO Luis Rojo flatly says are expanding at zero to one percent. That gap is the entire investment case, and it is built on share growth in the Tier 2 and Tier 3 customer base: more than 300 new customers and nearly 900 new customer-product combinations year to date. Two of the growth engines are genuinely fresh vocabulary for this company. MCT business and the MCT product line did not exist as top-ranked themes before this quarter, and they now carry the Specialty Products segment — Rojo describes a new innovation program pushing medium-chain triglycerides down into mid-tier price points. Spray foam and phthalic anhydride inside Polymers are older themes but still compounding: “The rigid business is strong, and we are growing a lot of share in a spray foam” — Dave Storms, Analyst · 2026-10-28. Neither MCT nor spray foam nor Tier 3 surfactants shows up anywhere in the market-wide keyword tape, which over the last twelve quarters has been almost entirely AI data centers, semiconductors, biotech readouts and energy. Stepan is running a company-unique story with essentially zero thematic confluence — no sector wave to ride, and no sector wave to hide behind.

What changed, and what quietly didn't

The clearest genuine change is Project Catalyst. Last quarter management committed to $60 million of 2026 pretax savings. This quarter, asked whether the 2027 incremental number was still $40 million, Rojo effectively raised it: “Instead of the 60, we are more in the $66 million to $70 million range” — Luis E. Rojo, President and CEO · 2026-10-28, with a $23 million quarterly run rate already in hand and an expectation of beating $25 million on average in 2027. That is a real, unhedged upward revision, and it's the sort of thing a management team only does when it believes the savings are locked. The tension is everywhere else. The pre-buying question came back — Mike Harrison asked it again, having heard in July that the entire $5-10 million Q2 EBITDA cushion was pulled-forward demand. A quarter ago the answer was categorical:

We believe probably between $5 million and $10 million, so for the midpoint of $5 million to $10 million EBITDA, is in fact all the pre-buying into Q2.
Luis Rojo, President and Chief Executive Officer · 2026-07-29

This time the framing softened: “Some of that was expected on the volume side, but a lot of that was expected on the margin side as well” — Luis E. Rojo, President and CEO · 2026-10-28, plus an invitation to average Q2's $74 million and Q3's $66 million into a $140 million two-quarter figure. That's defensible arithmetic — but it is also a walk-back dressed as transparency. Tellingly, pre buying was a top-five theme in the prior quarter and has since collapsed into decline; management would clearly prefer the subject retire. The Middle East conflict has undergone a similar tonal shift. In April it was an active constraint — “We could be growing faster than what we're growing now, but we don't have all the raw materials that we need” — Luis Rojo, Chief Executive Officer · 2026-04-28. By October the Middle East conflict is described as having "added volatility to fixed cost and supply chain" and is being reframed as an advantage, since Stepan's regional footprint and dual petrochemical/oleochemical feedstock slate let it compete where importers cannot. That is a theme maturing into a moat rather than disappearing.

The one macro thread that got worse

Crop productivity is the soft spot. Surfactant organic growth was led by consumer, construction, industrial and oilfield — partially offset by lower agricultural demand. Asked directly about a developing El Niño, Rojo conceded the macro backdrop is unhelpful across the ag complex but pointed to a $1 billion US tank-mix market and a $700 million Brazilian one where Stepan is, in his words, still in its "infant phase." Worth noting: the market's own theme-detection flagged el niño as one of the highest-momentum global keywords just two quarters ago — the agricultural weather risk is real and already being priced across other ag-exposed names, even if Stepan's own ag franchise is small enough to absorb it.

Balance sheet, tape, and what's left to prove

Deleveraging was a headline theme for several quarters and has, curiously, faded as it succeeded. Net debt sits at $536 million with leverage down to 2.4x from 2.7x, a $28.5 million land sale near Millsdale closes in October with proceeds earmarked for debt, and the dividend rose 2.5% for a 59th consecutive year. The keyword net leverage has slid down the company's own theme rankings precisely because it stopped being a problem — one of those silences that is itself informative. The stock has noticed. SCL is up roughly 30% in ninety trading days, a near-straight-line move into the print, yet still sits 50% below its 2021 high. At a market cap of $1.55 billion the re-rating is being paid for on recovery, not on level: price to net income of 22.8x versus a 54x peak, and price to sales at 0.5x. Free cash flow remains the nagging gap — the latest filed quarter showed an outflow, and management's own Q3 figure was only $8 million after a $32 million working capital build. So the bet is narrow and explicit: that 4% volume growth in a 0-1% market is structural share capture rather than a temporary gift from competitors' supply problems, and that Catalyst savings net of inflation actually reach the bottom line. The company has now been asked about both, quarter after quarter, and has answered with numbers rather than adjectives. What it has not done is demonstrate that a ceiling exists on raw material volatility — and with higher raw material costss still ranking near the top of its own themes, that is the variable nobody on this call controls.